论著摘要 |【CT】在接受酪氨酸激酶抑制剂治疗的EGFR突变的非小细胞肺癌患者中肿瘤异质性和无进展生存期之间的关联(双语版)

2017-09-14 18:15:50 admin 1

Association between Tumor Heterogeneity and Progression-Free Survival in Non-Small Cell Lung Cancer Patients with EGFR Mutations undergoing Tyrosine Kinase Inhibitors Therapy.

发表日期: 2016.10.18   来源:2016 IEEE 38th Annual International Conference of the. IEEE, 2016: 1268-1271.

作者:Song, J.1, Dong, D.2, Huang, Y.3, Zang, Y.2, Liu, Z.3, Tian, J.2

作者介绍:

1. Sino-Dutch Biomedical and Information Engineering School, Northeastern University, Shenyang, 110819, China

2. The Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China

3. Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

摘要

对于具有表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)患者,目前的分期方法不能准确预测酪氨酸激酶抑制剂(TKI)治疗后疾病复发的风险。开发一种非侵入性方法来预测个体是否可以受益于TKI治疗具有重大临床意义。在这项研究中,提出了一种影像组学方法,是否可以通过计算机断层扫描(CT)的纹理特征得到的非小细胞肺癌(NSCLC)患者的肿瘤异质性,来独立预测无进展生存期(PFS)。采用包含80例具有阳性EGFR突变的患者(中位PFS9.5个月)的主要数据集及72NSCLC(中位PFS10.2个月)患者的验证数据集进行预后试验。实验结果表明:“灰度共现聚类突”(风险比[HR]2.13,95%置信区间[CI]:(1.33,3.40),P = 0.010)和“短行程高灰度优势”(HR2.43,95CI:(1.46,4.05),P = 0.005)与主要数据集的PFS显著相关,并且这两个纹理特征也与验证组性能保持一致。我们的研究进一步支持肿瘤异质性的定量测量与EGFR突变的非小细胞肺癌患者的预后相关。

Abstract

For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, current staging methods do not accurately predict the risk of disease recurrence after tyrosine kinase inhibitors (TKI) therapy. Developing a noninvasive method to predict whether individual could benefit from TKI therapy has great clinical significance. In this research, a radiomics approach was proposed to determine whether the tumor heterogeneity of NSCLC, which was measured by the texture on computed tomography (CT), could make an independent prediction of progression-free survival (PFS). A primary dataset contained 80 patients (median PFS, 9.5 months) with positive EGFR mutations and a validation dataset contained 72 NSCLC (median PFS, 10.2 months) patients were used for prognosis trial. The experiment results indicated that the features: “Cluster Prominence of Gray Level Co-occurrence” (hazard ratio [HR]: 2.13, 95% confidence interval [CI]: (1.33, 3.40), P = 0.010) and “Short Run High Gray Level Emphasis of Run Length” (HR: 2.43, 95%CI: (1.46, 4.05), P = 0.005) were significantly associated with PFS in the primary dataset, and these two texture features also make a consistent performance on the validation cohort. Our study further supported that the quantitative measurement of tumor heterogeneity can be associated with prognosis of NSCLC patients with EGFR mutation.

 

关键词:

肿瘤,癌症,计算机断层扫描,患者治疗

Key Words:

tumours, cancer, computerised tomography, patient treatment

 

阅读原文:10.1109/EMBC.2016.7590937

 

 

 

 


慧影医疗科技(北京)有限公司

地点:北京市海淀区中关村东升科技园B2-C103

电话:400-890-9020

邮箱:radcloud@huiyihuiying.com

关闭
图片
图片
  • 人工智能诊断云平台